Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (33): 6179-6183.doi: 10.3969/j.issn.1673-8225.2010.33.024

Previous Articles     Next Articles

Ovidutus Ranae enzymatic hydrolyzate prevents osteoporosis in ovariectomized rats

Li Zhong-ping, Shen Hong-yi   

  1. Research Center for Health and Nutrition, Shanghai University of Traditional Chinese Medicine, Shanghai  201203, China
  • Online:2010-08-13 Published:2010-08-13
  • Contact: Shen Hong-yi, Doctor, Associate investigator, Research Center for Health and Nutrition, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China xhhc1503@sina.com
  • About author:Li Zhong-ping★, Master, Research assistant, Research Center for Health and Nutrition, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China lizhongping163@sina.com
  • Supported by:

    the Nutrition Foundation of Shanghai University of Traditional Chinese Medicine, No. 06jk01*

PDF

672

Abstract:

BACKGROUND: Previous studies showed that Oviductus Ranae plays a role in some symptoms of menopause. But its effect on prevention of osteoporosis required further investigation.
OBJECTIVE: To evaluate the effect of Oviductus Ranae enzymatic hydrolyzate on preventing osteoporosis in ovariectomized (OVX) rats.
METHODS: A total of 72 adult and female Wister rats were randomly divided into 6 groups with 12 rats in each group. The osteoporosis model was induced in rats by the OVX with the exception of the sham operation group. The medication commenced from 7 days after operation and lasted continuously for 12 weeks. The rats of sham operation group and the OVX group left were given equal volume of distilled water. Premarin group was perfused with 387.8 g/L Premarin (conjugate estrogens tablets) suspension 6. 67 g/(kg•d); 67.0, 26.8, 13.4 g/(kg•d) Oviductus Ranae enzymatic hydrolyzate groups were treated with corresponding dose of hydrolyzate. Food utilization rate was evaluated at the end of 3 months. All rats were sacrificed at the 12th week. Uterines, bone femur dry mass, bone femur ashes mass were weighed with electric scales; bone mineral density (BMD) was observed under DPX-L model X ray densimeter, bone calcium and bone phosphorus were observed under spectrometer.
RESULTS AND CONCLUSION: In the four medication groups, the high dose of Ovidutus Ranae enzymatic hydrolyzate group and the Premarin group had the lowest food utilization rate (P < 0.05). In the five OVX groups, uterins weighed was highest in Premarin group (P < 0.05). Both Premarin and moderate dose of Ovidutus Ranae enzymatic hydrolyzate retarded the bone loss (P < 0.05); the bone calcium and bone phosphorus of the three groups which received Ovidutus Ranae enzymatic hydrolyzate were higher than that of the OVX group (P < 0.05), but did not show any difference to that of the Premarin group (P > 0.05). The Ovidutus Ranae enzymatic hydrolyzate plays an important role in the prevention of postmenopausal osteoporosis as well as Premarin, but it had a lower side-effect in uterine hyperplasia.

CLC Number: